Naturally occurring substances and their role in chemo-protective effects

Central European Journal of Public Health

Volumn 21, Issue 4, 2013, Pages 213-219

  Bilecová Rabajdová, Miroslava ^a   Birková, Anna ^a   Urban, Peter ^a   Gregová, Kristína ^a   Ďurovcová, Eva ^b   Mareková, Mária ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b LABMED   (Slovakia)

Author keywords

Cancer; Chemoprevention; Inhibitors of metastasis; Malignant transformation

Indexed keywords

BIOLOGICAL PRODUCT; CALCITRIOL; DEGUELIN; DRUG DERIVATIVE; POLYPHENOL; PROTECTIVE AGENT; RETINOID; ROTENONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFUR DERIVATIVE; TERPENE;

HUMAN; NEOPLASM; REVIEW;

BIOLOGICAL PRODUCTS; CALCITRIOL; ESTROGEN RECEPTOR MODULATORS; HUMANS; NEOPLASMS; POLYPHENOLS; PROTECTIVE AGENTS; RETINOIDS; ROTENONE; SULFUR COMPOUNDS; TERPENES;

EID: 84897839069     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3886     Document Type: Review

References (74)

1. Usera AR, Dolan PM, Kensler TW, Posner GH. Antiproliferative, low-calcemic, fluorinated sulfone analogs of 1alpha,25-dihydroxyvitamin D3: chemical synthesis and biological evaluation. Bioorg Med Chem. 2007 Aug 15;15(16):5509-18.
2. Usera AR, Dolan P, Kensler TW, Posner GH. Novel alkyl side chain sulfone 1alpha,25-dihydroxyvitamin D3 analogs: a comparison of in vitro antiproliferative activities and in vivo calcemic activities. Bioorg Med Chem. 2009 Aug 1;17(15):5627-31.
3. Gandini S, Francesco FP, Johanson H, Bonanni B, Testori A. Why vitamin D for cancer patients? Ecancermedicalscience. 2009;3:160.
4. Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011 Mar;26(3):455-7.
5. Reid IR, Avenell A. Evidence-based policy on dietary calcium and vitamin D. J Bone Miner Res. 2011 Mar;26(3):452-4.
6. Roth DE. Vitamin D supplementation during pregnancy: safety considerations in the design and interpretation of clinical trials. J Perinatol. 2011 Jul;31(7):449-59.
7. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer-ready for prime time? N Engl J Med. 2011 Apr 14;364(15):1385-7.
8. Chesney RW. The five paradoxes of vitamin D and the importance of sunscreen protection. Clin Pediatr (Phila). 2012 Sep;51(9):819-27.
9. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013 Apr 1;19(7):1651-9.
10. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009 Nov 28;285(2):210-7.
11. Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, et al. Retinoids in cancer chemoprevention. Curr Cancer Drug Targets. 2004 May;4(3):285-98.
12. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000 Jul;21(7):1271-9.
13. Bao GC, Wang JG, Jong A. Increased p21 expression and complex formation with cyclin E/CDK2 in retinoid-induced pre-B lymphoma cell apoptosis. FEBS Lett. 2006 Jun 26;580(15):3687-93.
14. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, et al. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res. 2005 Jan 15;65(2):587-95.
15. Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatolog Treat. 2013 Jun;24(3):235-7.
16. Lee JA, Bae JW, Woo SU, Kim H, Kim CH. Correlation between COX-2 expression and hormone receptors in invasive ductal breast cancer. J Korean Surg Soc. 2010 Mar;78(3):140-8.
17. Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Maruyama T, Kawamori T. Inhibition of prostaglandin E2 signaling through the EP1 receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat. 2009 Nov;90(1-2):31-6.
18. Kundu JK, Hwang DM, Lee JC, Chang EJ, Shin YK, Fujii H, et al. Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets. Cancer Lett. 2009 Jan 8;273(1):86-97.
19. Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci. 2009 Nov 4;85(19-20):663-9.
20. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet. 2003 Jul 19;362(9379):230-2.
21. Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002 May;13(5):669-78.
22. Sugantha Priya E, Selvakumar K, Bavithra S, Elumalai P, Arunkumar R, Raja Singh P, et al. Anti-cancer activity of quercetin in neuroblastoma: an in vitro approach. Neurol Sci. In press.
23. Boghossian S, Hawash A. Chemoprevention in colorectal cancer-where we stand and what we have learned from twenty year's experience. Surgeon. 2012 Feb;10(1):43-52.
24. Gail MH. The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann N Y Acad Sci. 2001 Dec;949:286-91.
25. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005 Apr 15;65(8):3493-6.
26. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003 Jun;36(3):131-49.
27. Lønning PE. Aromatase inhibitors in breast cancer. Endocr Relat Cancer. 2004 Jun;11(2):179-89.
28. Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging. 2007;2(3):283-97.
29. Elkak AE, Mokbel K. Pure antiestrogens and breast cancer. Curr Med Res Opin. 2001;17(4):282-9.
30. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001 May;7(5):1230-6.
31. Miller WR, Bartlett J, Brodie AMH, Brueggemeier RW, di Salle E, Lønning PE, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist. 2008 Aug;13(8):829-37.
32. Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbø Y, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008 Oct 1;14(19):6330-5.
33. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007;9(3):R37.
34. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005 Sep;57(3):359-83.
35. Sun SY, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 2004 May 5;96(9):662-72.
36. Khan AQ, Khan R, Rehman MU, Lateef A, Tahir M, Ali F, et al. Soy isoflavones (daidzein & genistein) inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cutaneous inflammation via modulation of COX-2 and NF-κB in Swiss albino mice. Toxicology. 2012 Dec 16;302(2-3):266-74.
37. Liu MM, Huang Y, Wang J. Developing phytoestrogens for breast cancer prevention. Anticancer Agents Med Chem. 2012 Dec;12(10):1306-13.
38. Constantinou AI, White BE, Tonetti D, Yang Y, Liang W, Li W, et al. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer. 2005 Mar;41(4):647-54.
39. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010 Sep 15;24(18):1967-2000.
40. Schmitz-Dräger BJ, Lümmen G, Bismarck E, Fischer C. Prevention strategies for prostate cancer. Minerva Urol Nefrol. 2012 Dec;64(4):225-31.
41. Lee JH, Khor TO, Shu L, Su ZY, Fuentes F, Kong AN. Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther. 2013 Feb;137(2):153-71.
42. Miller PE, Snyder DC. Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutr Clin Pract. 2012 Oct;27(5):599-612.
43. Davalli P, Rizzi F, Caporali A, Pellacani D, Davoli S, Bettuzzi S, et al. Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev. 2012;2012:984219.
44. Paluszczak J, Krajka-Kuźniak V, Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett. 2010 Feb 1;192(2):119-25.
45. Vadhanam MV, Ravoori S, Aqil F, Gupta RC. Chemoprevention of mammary carcinogenesis by sustained systemic delivery of ellagic acid. Eur J Cancer Prev. 2011 Nov;20(6):484-91.
46. Umesalma S, Sudhandiran G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol. 2011 Jun 25;660(2-3):249-58.
47. D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita. 2007;43(4):348-61.
48. Dai J, Mumper RJ. Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules. 2010 Oct;15(10):7313-52.
49. Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors. 2013 Jan-Feb;39(1):27-36.
50. Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-12.
51. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1295-9.
52. Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010 Mar;5(1):61-74.
53. Han BS, Park CB, Takasuka N, Naito A, Sekine K, Nomura E, et al. A ferulic acid derivative, ethyl 3-(4'-geranyloxy-3-methoxyphenyl)-2-propenoate, as a new candidate chemopreventive agent for colon carcinogenesis in the rat. Jpn J Cancer Res. 2001 Apr;92(4):404-9.
54. van der Logt EM, Roelofs HM, Nagengast FM, Peters WH. Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis. 2003 Oct;24(10):1651-6.
55. Serafim TL, Carvalho FS, Marques MP, Calheiros R, Silva T, Garrido J, et al. Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem Res Toxicol. 2011 May 16;24(5):763-74.
56. Balakrishnan S, Manoharan S, Alias LM, Nirmal MR. Effect of curcumin and ferulic acid on modulation of expression pattern of p53 and bcl-2 proteins in 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Indian J Biochem Biophys. 2010 Feb;47(1):7-12.
57. Bergman M, Levin GS, Bessler H, Djaldetti M, Salman H. Resveratrol affects the cross talk between immune and colon cancer cells. Biomed Pharmacother. 2013 Feb;67(1):43-7.
58. Wang H, Zhang H, Tang L, Chen H, Wu C, Zhao M, et al. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis. Toxicology. 2013 Jan 7;303:139-46.
59. Maccario C, Savio M, Ferraro D, Bianchi L, Pizzala R, Pretali L, et al. The resveratrol analog 4,4'-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis. 2012 Nov;33(11):2172-80.
60. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, et al. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2013 May;73(7):754-62.
61. Fang Y, DeMarco VG, Nicholl MB. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. Cancer Sci. 2012 Jun;103(6):1090-8.
62. Mao JT, Nie WX, Tsu IH, Jin YS, Rao JY, Lu QY, et al. White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-{gamma} and 15-lipoxygenases. Cancer Prev Res (Phila). 2010 Sep;3(9):1132-40.
63. Saha A, Kuzuhara T, Echigo N, Suganuma M, Fujiki H. New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev Res (Phila). 2010 Aug;3(8):953-62.
64. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res. 2009 Aug 1;15(15):4885-94.
65. Inaba H, Nagaoka Y, Kushima Y, Kumagai A, Matsumoto Y, Sakaguchi M, et al. Comparative examination of anti-proliferative activities of (-)-epigallocatechin gallate and (-)-epigallocatechin against HCT116 colorectal carcinoma cells. Biol Pharm Bull. 2008 Jan;31(1):79-84.
66. Singh SV, Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis. 2012 Oct;33(10):1833-42.
67. Traka MH, Spinks CA, Doleman JF, Melchini A, Ball RY, Mills RD, et al. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer. 2010 Jul 13;9:189.
68. Singh SV, Kim SH, Sehrawat A, Arlotti JA, Hahm ER, Sakao K, et al. Biomarkers of phenethyl isothiocyanate-mediated mammary cancer chemoprevention in a clinically relevant mouse model. J Natl Cancer Inst. 2012 Aug 22;104(16):1228-39.
69. Lii CK, Tsai CW, Wu CC. Garlic allyl sulfides display differential modulation of rat cytochrome P450 2B1 and the placental form glutathione S-transferase in various organs. J Agric Food Chem. 2006 Jul 12;54(14):5191-6.
70. Chun HS, Kim HJ, Choi EH. Modulation of cytochrome P4501-mediated bioactivation of benzo[a]pyrene by volatile allyl sulfides in human hepatoma cells. Biosci Biotechnol Biochem. 2001 Oct;65(10):2205-12.
71. Aydemir G, Kasiri Y, Birta E, Béke G, Garcia AL, Bartók EM, et al. Lycopene-derived bioactive retinoic acid receptors/retinoid-X receptors-activating metabolites may be relevant for lycopene's anti-cancer potential. Mol Nutr Food Res. 2013 May;57(5):739-47.
72. Takahashi S, Sato S, Shirai T. Chemoprevention of prostate cancer. Nihon Rinsho. 2011 Jun;69 Suppl 5:56-60. (In Japanese.)
73. Parija T, Das BR. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene. Mol Biol Rep. 2003Mar;30(1):41-6.
74. Jia SS, Xi GP, Zhang M, Chen YB, Lei B, Dong XS, et al. Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells. Oncol Rep. 2013 Jan;29(1):349-54.